Medicamen Biotech Limited (MEDICAMEQ.BO)
- Previous Close
419.65 - Open
428.90 - Bid 491.55 x --
- Ask 491.00 x --
- Day's Range
428.90 - 496.00 - 52 Week Range
356.75 - 903.50 - Volume
12,595 - Avg. Volume
4,318 - Market Cap (intraday)
6.215B - Beta (5Y Monthly) 1.34
- PE Ratio (TTM)
54.23 - EPS (TTM)
9.06 - Earnings Date May 27, 2024 - May 31, 2024
- Forward Dividend & Yield 1.00 (0.24%)
- Ex-Dividend Date Sep 20, 2023
- 1y Target Est
--
Medicamen Biotech Limited researches, develops, manufactures, markets, sells, and distributes pharmaceutical formulations and APIs in India. The company offers a range of products, including tablets, such as non-beta lactam tablets; capsules comprising beta and non-beta lactam capsules; liquid and dry syrups; and ointments and creams. It also provides oral solid and liquid products. The company's products are used in various therapeutic areas, such as gastrointestinal, pain management, anti-infectives, pediatrics, dermatology, gynecology and rheumatology, diabetology, cardiology, oncology, and the central nervous system. Medicamen Biotech Limited was incorporated in 1993 and is based in New Delhi, India.
medicamen.com/388
Full Time Employees
March 31
Fiscal Year Ends
Sector
Related News
Performance Overview: MEDICAMEQ.BO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MEDICAMEQ.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MEDICAMEQ.BO
Valuation Measures
Market Cap
5.31B
Enterprise Value
5.46B
Trailing P/E
46.37
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.06
Price/Book (mrq)
2.66
Enterprise Value/Revenue
3.20
Enterprise Value/EBITDA
21.79
Financial Highlights
Profitability and Income Statement
Profit Margin
7.44%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
1.71B
Net Income Avi to Common (ttm)
126.93M
Diluted EPS (ttm)
9.06
Balance Sheet and Cash Flow
Total Cash (mrq)
134.28M
Total Debt/Equity (mrq)
14.52%
Levered Free Cash Flow (ttm)
--
Research Analysis: MEDICAMEQ.BO
Company Insights: MEDICAMEQ.BO
MEDICAMEQ.BO does not have Company Insights